IN2013MU03426A - - Google Patents

Info

Publication number
IN2013MU03426A
IN2013MU03426A IN3426MU2013A IN2013MU03426A IN 2013MU03426 A IN2013MU03426 A IN 2013MU03426A IN 3426MU2013 A IN3426MU2013 A IN 3426MU2013A IN 2013MU03426 A IN2013MU03426 A IN 2013MU03426A
Authority
IN
India
Prior art keywords
release composition
relates
modified
oxcarbazepine
salts
Prior art date
Application number
Inventor
Girish Kumar Jain
Manohar Lalge
Vinayak Kadam
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to IN3426MU2013 priority Critical patent/IN2013MU03426A/en
Publication of IN2013MU03426A publication Critical patent/IN2013MU03426A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a solid oral modified-release composition comprising oxcarbazepine or salts thereof. In particular, the present invention relates to a solid oral modified-release composition comprising matrix of oxcarbazepine or salts thereof with one or more pharmaceutically acceptable excipients; wherein the composition is devoid of excipients having pH-dependent solubility. The invention further relates to a process of preparing such modified-release composition and its use in treatment of epileptic seizures.
IN3426MU2013 2013-10-30 2013-10-30 IN2013MU03426A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN3426MU2013 IN2013MU03426A (en) 2013-10-30 2013-10-30

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3426MU2013 IN2013MU03426A (en) 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
IN2013MU03426A true IN2013MU03426A (en) 2015-07-31

Family

ID=54397480

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3426MU2013 IN2013MU03426A (en) 2013-10-30 2013-10-30

Country Status (1)

Country Link
IN (1) IN2013MU03426A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980622B1 (en) 2020-06-17 2024-05-14 Apotex Inc. Oxcarbazepine extended release dosage form

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980622B1 (en) 2020-06-17 2024-05-14 Apotex Inc. Oxcarbazepine extended release dosage form

Similar Documents

Publication Publication Date Title
PH12017502297A1 (en) Antibacterial compounds
IN2015DN01156A (en)
MX2015018048A (en) Substituted benzofuranyl and benzoxazolyl compounds and uses thereof.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX364486B (en) Pyridazinone-amides derivatives.
UA118380C2 (en) Substituted dihydroisoquinolinone compounds
PH12016501122A1 (en) Delayed release compositions of linaclotide
IN2015KN00262A (en)
MX2021001169A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
IN2014DN06966A (en)
UA117032C2 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EA201992832A1 (en) SCREAM INTRODUCTION ADAMTS13
IN2013MU01985A (en)
MD20160111A2 (en) Cycloalkyl-linked diheterocycle derivatives
MX2019000677A (en) B-cell-mimetic cells.
PH12015500399A1 (en) Azaindolines
IN2013MU01111A (en)
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
MX2018001684A (en) Method of wound healing.
MX2020006075A (en) Bendamustine pharmaceutical compositions.
IN2013MU03426A (en)
MX2011012233A (en) Topical retinoid solutions.